[HTML][HTML] Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
Abstract Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …
[HTML][HTML] Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
SW Waijer, P Vart, DZI Cherney, GM Chertow… - Diabetologia, 2022 - ncbi.nlm.nih.gov
Methods DAPA-CKD was a double-blind, placebo-controlled trial that randomised patients
with an eGFR of 25–75 ml min− 1 [1.73 m]− 2 and urinary albumin/creatinine ratio (UACR) …
with an eGFR of 25–75 ml min− 1 [1.73 m]− 2 and urinary albumin/creatinine ratio (UACR) …
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
SW Waijer, P Vart, DZI Cherney, GM Chertow… - …, 2022 - search.proquest.com
Methods DAPA-CKD was a double-blind, placebo-controlled trial that randomised patients
with an eGFR of 25–75 ml min− 1 [1.73 m]− 2 and urinary albumin/creatinine ratio (UACR) …
with an eGFR of 25–75 ml min− 1 [1.73 m]− 2 and urinary albumin/creatinine ratio (UACR) …
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
SW Waijer, P Vart, DZI Cherney, GM Chertow… - Diabetologia, 2022 - europepmc.org
Methods DAPA-CKD was a double-blind, placebo-controlled trial that randomised patients
with an eGFR of 25-75 ml min-1 [1.73 m]-2 and urinary albumin/creatinine ratio (UACR) of≥ …
with an eGFR of 25-75 ml min-1 [1.73 m]-2 and urinary albumin/creatinine ratio (UACR) of≥ …
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
SW Waijer, P Vart, DZ Cherney, GM Chertow… - …, 2022 - discovery.ucl.ac.uk
AIMS/HYPOTHESIS: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
SW Waijer, P Vart, DZI Cherney… - …, 2022 - utsouthwestern.elsevierpure.com
Aims/hypothesis: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
SW Waijer, P Vart, DZI Cherney, GM Chertow, N Jongs… - 2022 - pubmed.ncbi.nlm.nih.gov
Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
SW Waijer, P Vart, N Jongs, HJL Heerspink… - 2022 - cabidigitallibrary.org
Abstract Aims/hypothesis: In the Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
SW Waijer, P Vart, DZI Cherney, GM Chertow… - Diabetologia, 2022 - eprints.gla.ac.uk
Aims/hypothesis: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
SW Waijer, P Vart, DZI Cherney, GM Chertow… - Diabetologia, 2022 - research.rug.nl
AIMS/HYPOTHESIS: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …
Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney …